586408-20-0

Upstream product

• 14094-37-2 6-amino-5-bromo-1-methylpyrimidine-2,4(1H,3H)-dione 
• 70404-28-3 6-amino-5-(benzylamino)-1-methylpyrimidine-2,4(1H,3H)-dione 
• 2434-53-9 6-amino-1-methyluracil 
• 18997-19-8 Chloromethyl pivalate 
• 56025-86-6 7-benzyl-3-methylxanthine 

Relevant academic research and scientific papers

Easy preparative scale syntheses of labelled xanthines: Caffeine, theophylline and theobromine

Several easy preparative scale (0.5-1.5 g) syntheses of deuterium labelled caffeine, theophylline and theobromine are described. Some new selective syntheses of theophylline and theobromine have been developed. Labelled xanthines are of great interest in qualitative or quantitative isotope dilution-mass spectrometry, coupled with gas or liquid chromatography, currently performed in anti-doping and forensic laboratories. Copyright

COMBINATION DRUG

The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2).

Xanthine derivatives as DPP-IV inhibitors

The present invention provides novel compounds exhibiting an excellent DPPIV inhibition effect. The compounds are represented by the formula: wherein, m is 0 or 1; n is 0; R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, and R42 each represent a hydrogen atom; X represents an alkynyl group, an aryl group, and such, which group may be substituted; and, R1 and R2 each independently represents a hydrogen atom, an alkyl group, an alkoxyl group, or such, or salts or hydrates thereof.